The peptide therapeutics market size is projected to reach US$ 73.63 billion by 2031 from US$ 29.35 billion in 2023. The market is expected to register a CAGR of 11.5% in 2023–2031. Growing popularity reducing the pace of manufacturing of peptide drugs and adoption of new technologies are likely to remain key peptide therapeutics market trends.
As the global burden of chronic diseases increases, the demand for targeted and efficient therapeutic approaches increases. With their precision and specificity, peptide therapeutics are proving to be a compelling solution that meets the therapeutic needs of various chronic diseases. Robust research pipelines promise a future full of novel and breakthrough peptide therapeutics. The shift toward personalized medicine is consistent with the unique properties of peptide therapeutics. As peptides show promise in treating rare diseases, pharmaceutical companies focus on developing therapeutic solutions for niche patient populations. Innovations in synthetic methods lead to more complex and specialized peptides, expanding the therapeutic arsenal available to healthcare professionals. Further, combined efforts in research initiatives between scientists and market players drive innovation in the peptide therapeutics market. Additionally, partnerships and alliances create synergies that advance the development of cutting-edge peptide-based therapies. However, stringent regulations and high drug development costs are expected to restrain market growth.
The peptide therapeutics market is emerging as a dynamic and promising sector within the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. Peptide therapeutics composed of short amino acid sequences have attracted considerable attention due to their specificity, efficacy, and potential applications in various therapeutic areas. This emerging market stands at the intersection of innovation and medical science and is poised to reshape the healthcare landscape. The market includes various peptides, from naturally occurring to synthetic analogs, designed for improved therapeutic results. These peptides are versatile agents targeting specific receptors, enzymes, or cellular mechanisms, making them a valuable tool in precision medicine.
As per an article in the National Library of Medicine, infectious diseases remain a leading cause of sickness and mortality worldwide, causing more than 52 million deaths per year worldwide. According to the IDF published in December 2021, an estimated 14 million adults in Mexico have diabetes. Peptides such as amide (GLP-1) are effective in treating diabetes. In February 2022, the Nova Scotia provincial government reported that Nova Scotians have registered in pharmacare programs that would begin switching to a biosimilar version of certain biologic medicines, including some insulins and medications, for the treatment of Crohn's disease and rheumatism. The increasing cases of some metabolic disorders, such as organ dysfunction, genetic disorders, and mitochondrial dysfunction, are one of the factors that drive the market growth. The progressive storage of glucocerebrosides in macrophages, primarily in the bone, bone marrow, spleen, and liver are the indications of Gaucher disease (GD) which is an autosomal recessive lysosomal storage disorder. As per the Journal of Pediatric Haematology/Oncology (JPHO), in July 2022, the prevalence of GD cases per 100,000 live births worldwide was 1.5. Therefore, the high prevalence of infectious and metabolic diseases drives the demand for peptide therapeutics for treating these diseases, thereby boosting market growth.
The most common peptide indications are oncology, endocrinology, and metabolic diseases. Other peptide target areas that have received attention include gastroenterology, cardiovascular disease, dermatology, bone diseases, and sexual dysfunction. Due to their high immunogenicity, peptide vaccines also have great potential to become an alternative to classical vaccines as they are completely synthetic and do not cause undesirable side effects. To overcome their limitations, various modifications of peptides have been introduced. Furthermore, the ongoing studies related to the application of peptides are expected to positively impact the pipeline, thereby providing lucrative opportunities for market growth. Some peptide drug pipelines are as follows:
FAP-2286
Oncology-FAP expressing tumours
Phase-I clinical trials
3B 401
Neuroendocrine tumors
Pre-clinical trials
ALY688
Ophthalmology-Dry eye disease
Phase-II clinical trials
ALY688SR
Liver diseases and obesity
Phase-I clinical trials
Source: Issar Pharma, Willing Wellness
Key segments that contributed to the derivation of the peptide therapeutics market analysis are component, application, and end user.
The geographic scope of the peptide therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
North America has dominated the peptide therapeutics market. The growth of the market in North America is attributed to the renowned academic institutions, state-of-the-art laboratories, and collaborations between science and industry contribute to a vibrant R&D ecosystem that promotes the discovery and development of novel peptides with therapeutic potential. In North America, the biotechnology sector in plays an important role in developing peptide therapeutics. The presence of leading biotech companies and a supportive regulatory environment promote translating research findings into clinically viable peptide-based treatments, positioning North America as a leader in the global peptide therapeutics space. The prevalence of chronic diseases in North America highlights the need for advanced therapeutic solutions. With their targeted mechanisms of action, peptide therapeutics are proving to be promising candidates for treating diseases such as diabetes, cardiovascular diseases (CVDs), and various types of cancer. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Peptide Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Peptide Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 29.35 Billion |
| Market Size by 2031 | US$ 73.63 Billion |
| Global CAGR (2023 - 2031) | 11.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2023-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Peptide Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Peptide Therapeutics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The peptide therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for peptide therapeutics: